PredictImmune aims to develop and commercialise a series of biomarker tests to guide physicians in the treatment of patients with immune-mediated disease, through prediction of long-term clinical prognosis

The first test, PredictSURE IBD™ is a validated and CE-marked test for guiding treatment options in inflammatory bowel disease, Crohn’s disease and ulcerative colitis.

It was discovered and developed in the laboratory of Professor Kenneth Smith, Head of the Department of Medicine at the University of Cambridge in collaboration with gastroenterologists at Cambridge University Hospitals NHS Foundation Trust. His group has published on the underlying biology of the prognostic biomarkers that comprise the test, which also have relevance in other inflammatory and autoimmune diseases, including vasculitis and Lupus (SLE), where clinical research and development is ongoing in the Smith laboratory. Independent market research indicates that physicians, patients and payers will recognise the value of personalised treatment guidance in Crohn’s disease and ulcerative colitis.

CIC point of contact: Michael Anstey 

More from our Portfolio

PolyProx Therapeutics

LIFE SCIENCES SEED
View company profile polyprox.com

Carrick Therapeutics

LIFE SCIENCES GROWTH
View company profile carricktherapeutics.com

Gyroscope Therapeutics

LIFE SCIENCES GROWTH
View company profile gyroscopetx.com